692 related articles for article (PubMed ID: 28689307)
1. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
4. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
Ward L; Bardai G; Moffatt P; Al-Jallad H; Trejo P; Glorieux FH; Rauch F
Calcif Tissue Int; 2016 Jun; 98(6):566-72. PubMed ID: 26815784
[TBL] [Abstract][Full Text] [Related]
5. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
6. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
8. Novel Mutations in SERPINF1 Result in Rare Osteogenesis Imperfecta Type VI.
Wang JY; Liu Y; Song LJ; Lv F; Xu XJ; San A; Wang J; Yang HM; Yang ZY; Jiang Y; Wang O; Xia WB; Xing XP; Li M
Calcif Tissue Int; 2017 Jan; 100(1):55-66. PubMed ID: 27796462
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
11. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Aström E; Jorulf H; Söderhäll S
Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
[TBL] [Abstract][Full Text] [Related]
13. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
[TBL] [Abstract][Full Text] [Related]
14. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
16. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
17. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
20. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
